Table 2 Phase II, first-line clinical trials of cetuximab in combination with various chemotherapeutic agents
Agents | n(tumor site) | RR (%) | PFS/TTP (month) | OS (month) |
|---|---|---|---|---|
mFOLFOX6 + cetuximab[41] | 50 (GC) | 50 | 5.5 | 9.9 |
Cisplatin + docetaxel + cetuximab[42] | 72 (GC or GEJC) | 41.2 | 5 | 9 |
Cetuximab + FOLFOX4[43] | 25 (GC) | 36 | 6.5 | 10.6 |
Oxaliplatin + irinotecan + cetuximab[44] | 51 (GC) | 63 | 5.8 | 8.9 |
Oxaliplatin + folic acid + 5-FU + cetuximab[45] | 52 (GC) | 65 | 7.6 | 9.5 |
Oxaliplatin + capecitabine + cetuximab[46] | 44 (GC) | 52.3 | 6.5 | 11.8 |
Irinotican + folic acid + 5-FU + cetuximab[47] | 49 (GC or GEJC) | 46 | 9 | 16.5 |
Epirubicin + cisplatin +5-FU + cetuximab FOLFOX + cetuximab Irinotican + cisplatin + cetuximab[48] | 245 (GC or GEJC) randomized | 58 51 38 | 5.6 5.75 | 10 10 8.6 |
Cisplatin + 5-FU + LV + cetuximab[49] | 35 (GC) | 68.6 | 11 | 14.5 |
Oxaliplatin + irinotecan + cetuximab[50] | 51 (GC) | 63 | 5.8 | 8.9 |
Docetaxel + oxaliplatin Docetaxel + oxaliplatin + cetuximab[51] | 150 (GC or GEJC) randomized | 24 29 | 4.7 5.1 | 9 8.5 |